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Factors	 at	 the	 level	 of	 family/healthcare	worker,	 organization,	 and	 system	 are	 ne-
glected	 in	 medication	 nonadherence	 research	 in	 heart	 transplantation	 (HTx).	 The	
4-	continent,	11-	country	 cross-	sectional	Building	Research	 Initiative	Group:	Chronic	









ence: patient level:	 barriers	 to	 taking	 immunosuppressants	 (odds	 ratio	 [OR]:	 11.48);	
smoking	(OR:	2.19);	family/healthcare provider level:	frequency	of	having	someone	to	
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1  | INTRODUCTION
Immunosuppressant	 nonadherence	 entails	 serious	 risks	 in	 solid	
organ	 transplantation	 (Tx),	 including	 heart	 transplantation	
(HTx).1,2	Based	on	the	ABC	taxonomy,	medication	adherence	has	
3	 phases:	 initiation,	 implementation,	 and	 discontinuation,	 and	
is	defined	as	 “the	extent	 to	which	a	patient’s	actual	dosing	cor-
responds	 to	 the	 prescribed	 dosing	 regimen.”3	 Nonadherence	 is	
linked	 to	 poor	 posttransplant	 outcomes	 including	 late	 acute	 re-
jection	and	graft	loss.2,4,5
Knowledge	of	immunosuppressive	nonadherence	factors	aids	
identification	 of	 at-	risk	 patients	while	 exposing	 leverage	points	
for	 interventions.6	 To	 date,	 in	 addition	 to	 patient-	related	 vari-
ables,	confirmed	factors	relate	to	sociodemographics,	therapies,	
or	conditions,1,7,8	with	some	evidence	indicating	links	to	health-
care teams and providers.9-12	However,	 the	 focus	has	been	pri-
marily	on	patient-	level	factors.1,8,13,14	 In	fact,	most	patient-	level	
factors	 are	 only	 weakly	 associated	 with	 medication	 nonadher-
ence,	 suggesting	 that	 other-	level	variables	 also	 play	 roles.6,11,15 
In	addition,	few	studies	exploit	theoretical	models	that	guide	se-
lection	of	factors	for	investigation.16-18
Therefore,	 we	 favor	 an	 ecological	 perspective	 (eg	
Bronfenbrenner’s	model6,19,20)	that	positions	the	transplant	patient	
within	 the	 healthcare	 system’s	micro	 (family/healthcare	 provider),	
meso	 (transplant	 center),	 and	 macro	 (healthcare	 system)	 levels	
(Figure	1).6,21–32	 Reflecting	 this	 perspective,	 a	multilevel	 approach	
to	medication	nonadherence	is	novel,15,33 as multilevel medication 
nonadherence	 factors	 have	 received	 little	 attention	 in	 transplan-





With	 this	 in	 mind,	 the	 main	 hypothesis	 of	 the	 multicon-
tinental	 “Building	 Research	 Initiative	 Group:	 Chronic	 Illness	
Management	 and	 Adherence	 in	 Transplantation	 (BRIGHT)”	
study	 was	 that	 multilevel	 factors	 are	 associated	 with	 imple-
mentation	 phase	 immunosuppressant	 nonadherence	 in	 adult	
HTx	recipients.
2  | MATERIALS AND METHODS















>6	months,	who	worked	 at	 least	 50%	 in	direct	 clinical	 practice	 and	




Prior	 to	 data	 collection,	 ethical	 approval	was	 obtained	 from	 the	
University	 Hospitals	 of	 Leuven	 (Belgium)	 ethics	 committee,	 and	 all	






and	its	selected	multilevel	correlates	 involved	5	 instruments:	 (1)	the	
BRIGHT	patient	interview	questionnaire;	(2)	the	BRIGHT	patient	self-	
report	questionnaire;	(3)	the	BRIGHT	structured	form	for	medical	re-
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Immunosuppressant nonadherence	(implementation	phase)	was	as-
sessed	via	the	Basel	Assessment	of	Adherence	to	Immunosuppressive	




dose	 reductions.	 Patients	 scored	 their	 adherence	 over	 the	 past	
4	weeks.	Any	 deviation	 in	 taking,	 timing,	 or	 dosing	was	 considered	
nonadherence.34	 The	 instrument’s	 concurrent	 validity	 was	 demon-
strated	in	kidney36	and	predictive	validity	(regarding	late	acute	rejec-
tion	incidence)	in	liver	Tx	recipients.37
Multilevel medication nonadherence correlates	 were	 assessed	 via	
	validated	 instruments	 and	 investigator-	developed	measures	 (Appendix	
S1)	 (see	BRIGHT	methods	article34).	At	 the	patient	 level,	we	applied	






Working	 from	 an	 ecological	 perspective,	 the	 model	 of	
Bronfenbrenner	 et	al6,19,20	 (Figure	1)	 supported	 9	 micro-	 (interper-
sonal	 relationships,	 eg	 family,	 healthcare	 providers),	 32	 meso-	 (re-
















Descriptive	 data	 analysis	 included	 appropriate	 measures	 of	 central	




psychometric	 analyses	 were	 performed	 (Appendix	 S1).	 The	 dimen-
sionality	of	instruments	was	checked	using	(un)rotated	principal	com-
ponent	analyses	and	Cronbach’s	α	(Appendix	S1).
To	 identify	 multilevel	 correlates	 of	 medication	 adherence,	 we	
first	predicted	nonadherence	via	 simple	 logistic	 regression	analyses,	
invoking	 generalized	 estimating	 equations	 to	 account	 for	 possible	
within-	center	 subject	 correlations.40	 Variables	 whose	 odds	 ratios	
(ORs)	 suggested	 associations	 (ie	 confidence	 intervals	 [CIs]	 not	 in-
cluding	1.00)	were	subjected	to	multiple	 logistic	 regression	analysis.	
Constructing	 this	 model	 required	 a	 sequential	 approach	 including	
blockwise	 entry	 of	 variable	 groups	 at	 each	 level,	 starting	 with	 the	
Integrative	Model	of	Behavioral	prediction.	Block 1	 included	barriers	
and	intention,	the	factors	most	proximal	to	behavior;	Block 2 included 
attitudes,	 perceived	 norms,	 and	 self-	efficacy,	 which	 directly	 impact	





















Table	1	and	Figure	2	 show	demographic	 information	 for	 the	36	par-
ticipating	centers.	The	majority	(n	=	19,	52.8%)	were	large	centers.34,42 
They	handled	2523	eligible	patients.	We	 invited	1677	patients	 (ran-
dom	 selection;	 see	Materials	 and	Methods)	 to	 participate,	 of	whom	
244	declined	and	36	died	before	completing	the	questionnaire,	 leav-
ing	1397	patient	participants	who	completed	questionnaires	(Figure	3)	
(participation	 rate:	 83.3%;	mean	 age:	 53.6	years	 (standard	 deviation	







3.2 | Prevalence of nonadherence to 
immunosuppressants (implementation phase)
The	overall	prevalence	of	implementation	phase	immunosuppressant	
nonadherence	 was	 34.1%.	 Taking	 nonadherence	 (ie	 missing	 doses)	




Total sample Adherers Nonadherers Bivariate analysis 
N; mean ± SD  
N (%)a
N; mean ± SD  
N (%)b
N; mean ± SD  
N (%)b
Odds ratio  
(95% CI)
Block 1: Patient level: proximal variables based on Integrative Model of Behavioral Prediction 
Barriers	to	take	immunosuppressants	
as	prescribedd





1377;	4.69	±	0.53 865;	4.75	±	0.49 512;	4.59	±	0.59 0.58	(0.44-	0.77)c























1378; 4.34 ± 0.48 865; 4.43 ± 0.84 513;	4.19	±	0.83 0.72	(0.64-	0.81)c
Block 3: Patient level: variables derived from empirical evidence (sociodemographic, clinical, treatment- , condition, and patient- related factors)
Sociodemographic	factors
Genderd Male 1011	(72.73%) 638	(73.17%) 373	(72.01%) 0.94	(0.72-	3.57)











































Raced White 1186	(85.88%) 755	(86.99%) 431	(84.02%) 0.79	(0.54-	1.15)


























































N	dosing	times/d 1384; 2.04 ± 0.25 869;	2.04	±	0.24 515; 2.05 ± 0.26 1.26	(0.78-	2.03)
Time	since	transplantationd Years 1380; 3.36 ± 1.38 867;	3.33	±	1.39 513; 3.41 ± 1.37 1.04	(0.98-	1.11)
(Continues)
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Variables Values/scoring
Total sample Adherers Nonadherers Bivariate analysis 
N; mean ± SD  
N (%)a
N; mean ± SD  
N (%)b
N; mean ± SD  
N (%)b
Odds ratio  
(95% CI)
Condition-	related	factors
Depressive	symptomsd Sum	score	0	to	56 1340; 1.37 ± 0.60 829;	1.35	±	0.62 511;	1.39	±	0.55 1.01	(0.99-	1.01)
History	of	diabetes	
pretransplantd
Yes 366	(26.24%) 231	(26.34%) 135	(26.06%) 0.99	(0.78-	1.24)
Posttransplant	BMI	at	time	of	
enrollmentd

















1368;	6.82	±	2.39 859;	6.95	±	2.39 509;	6.62	±	2.37 0.94	(0.90-	0.99)c
Daytime	sleepinessd 0	(not	at	all	sleepy)	 
to	10	(very	sleepy)





1376; 1.08 ± 0.41 863; 1.07 ± 0.43 513;	1.09	±	0.39 1.13	(0.89-	1.43)
Currently	smoking	or	stopped	
<1	y	agod
Yes 90	(6.57%) 41	(4.77%) 49	(9.61%) 2.12	(1.46-	3.08)c
Health	literacy:	confidence	filling	
out	medical	forms	by	oneselfd
Adequate	literacy 912	(66.86%) 560	(65.04%)	 352	(69.98%) 1.25	(0.97-	1.62)
Nonadherence	to	physical	
activity	recommendationsd
















0	(never)	to	5	(always) 1377	(3.67	±	0.81) 867	(3.71	±	0.80) 510	(3.59	±	0.82) 0.83	(0.72-	0.96)c
Nonadherence	to	dietary	
guidelinesd
Adherent 232	(16.61%) 69	(13.27%) 163	(18.59%) 1.49	(1.06-	2.10)c
Block 4: Micro level (family/healthcare provider)
Social	support	(practical	support	
dimension)d
1	(never)	to	5	(all	the	time) 1378;	1.78	±	0.99 864;	1.73	±	0.98 514; 1.84 ± 1.00 1.12	(0.99-	1.26)
Social	support	(emotional	
dimension)d
1	(never)	to	5	(all	the	time) 1380; 3.58 ± 1.24 866; 3.61 ± 1.25 514; 3.51 ± 1.22 0.94	(0.85-	1.03)
Patient	is	a	member	of	a	patient	
organizationd





















Yes 1368	(98.49%) 859	(98.62%) 509	(98.26%) 0.79	(0.35-	1.79)
Trust	in	the	healthcare	teamd 1	(very	low	trust)	to	5	
(very	high	trust)
1378;	4.59	±	0.49 867; 4.62 ± 0.46 511; 4.55 ± 0.54 0.75	(0.60-	0.94)c
TABLE  1  (Continued)
(Continues)
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Variables Values/scoring
Total sample Adherers Nonadherers Bivariate analysis 
N; mean ± SD  
N (%)a
N; mean ± SD  
N (%)b
N; mean ± SD  
N (%)b






1379;	4.65	±	0.72 866; 4.66 ± 0.76 513; 4.63 ± 0.67 0.95	(0.79-	1.15)
Block 5: Meso level: transplant 
center (characteristics and 






patient	n	=	877a patient	n	=	520a  
Type	of	transplant	centere University	teaching 30	(83.33%) 739	(84.26%) 414	(79.62%) 0.73	(0.48-	1.10)	
Location	of	the	transplant	
programe
Urban 32	(88.89%) 786	(89.62%) 449	(86.35%) 0.73	(0.42-	1.27)
Years	since	start	of	the	transplant	
programe 


























35;	9.64	±	4.81 861; 10.45 ± 4.82 513;	9.71	±	4.49 0.97	(0.93-	1.00)































































questions or emergencies is an 
Advanced	Practice	Nursee
Yes 2	(5.56%) 63	(7.18%) 27	(5.19%) 0.71	(0.30-	1.67)
TABLE  1  (Continued)
(Continues)
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Variables Values/scoring
Total sample Adherers Nonadherers Bivariate analysis 
N; mean ± SD  
N (%)a
N; mean ± SD  
N (%)b
N; mean ± SD  
N (%)b




questions or emergencies is a 
registered nursee 
Yes 7	(19.44%) 135	(15.39%) 95	(18.27%) 1.23	(0.88-	1.69)





Yes 34	(58.62%) 499;	0.48	±	0.44 364; 0.46 ± 0.43 0.90	(0.56-	1.46)
The	clinic	has	someone	with	the	
title	of	care	coordinatorf 
Yes 49	(49.00%) 877;	0.49	±	0.41 520; 0.54 ± 0.40 1.40	(0.89-	2.19)
Patient’s	perspective	of	chronic	
illness management implemented 
in	HTx	program	(PACIC)d

















100;	3.39	±	0.43 877; 3.37 ± 0.38 520;	3.39	±	0.34 1.14	(0.69-	1.87)
Opportunities	exist	in	the	
transplant	program	for	pretrans-
plant patients to meet or interact 
with	posttransplant	recipientsf 
Yes 97	(97.00%) 877;	0.96	±	0.12 520;	0.97	±	0.11 2.32	(0.87-	6.18)
Self-	management	support	
interventions are provided during 
long-	term	followupf 
Yes 67	(67.00%) 877;	0.59	±	0.39	 522; 0.64 ± 0.37 1.73	(0.87-	6.18)
Refill	of	immunosuppressants:	
pick-	up	at	local	pharmacyd 
Yes 1117	(81.53%) 716	(83.16%) 401	(78.78%) 0.75	(0.51-	1.10)
Refill	of	immunosuppressants:	
hospital	pharmacyd 
Yes 305	(22.36%) 184	(21.50%) 121	(23.82%) 1.14	(0.82-	1.60)
Refill	of	immunosuppressants:	
physician’s	officed 
Yes 31	(2.28%) 12	(1.40%) 19	(3.78%) 2.76	(1.57-	4.85)c
Refill	of	immunosuppressants:	
online orderd 
Yes 114	(8.43%) 66	(7.74%) 48	(9.60%) 1.27	(0.86-	1.87)
Refill	of	immunosuppressants:	
telephone	orderd 
Yes 262	(19.42%) 156	(18.37%) 106	(21.20%) 1.20	(0.81-	1.76)
Refill	of	immunosuppressants:	
otherd 
Yes 23	(2.12) 14	(2.02) 9	(2.29) 1.16	(0.76-	1.78)
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was	reported	by	14.7%	and	timing	nonadherence	(>2	hours	deviation	
from	dosing	schedule)	by	26.5%	of	patients.













variables)	frequency of having someone to help read health-related materials 
(a	protective	factor),	was	retained,	along	with	3	of	Block	5’s	meso-	level	
variables	(medication pick-up at the physician office; clinicians reporting tar-
geting nonadherent patients with adherence interventions).	Finally,	in	Block	
6’s	macro-	level	factors,	we	noted	some	collinearity	between	employment 
and out-of-pocket expenses.	As	only	8%	of	employment’s	variability	was	





currently	 smoking	 or	 having	 stopped	 less	 than	 a	year	 ago	 [OR:	 2.19;	
95%	CI,	1.35-	3.56];	medication	pick-	up	at	physician’s	office	[OR	=	2.31;	










Our	 sensitivity	 analyses	 confirmed	 all	 of	 the	 included	 variables’	
relationships	 to	nonadherence.	However,	barriers	 to	 taking	 immuno-









the	first	 in	chronically	 ill	patient	populations6,15,33	 to	simultaneously	
investigate	patient-	,	healthcare	provider/family-	,	healthcare	organiza-
tion-	and	healthcare	system-	related	factors’	associations	with	medi-




tation	phase	nonadherence	 to	 immunosuppressants	 is	 substantial	 in	
Variables Values/scoring
Total sample Adherers Nonadherers Bivariate analysis 
N; mean ± SD  
N (%)a
N; mean ± SD  
N (%)b
N; mean ± SD  
N (%)b













































prevailing	 perspective—which	 assigns	 patients	 all	 responsibility	 for	
nonadherence—is	incorrect.










ers	 than	 to	 rational	 ones.	 Self-	efficacy,	 a	 factor	 previously	 associated	



















ence.	Medication	pick-	up	 at	 the	physician’s	office	vs	 at	 a	pharmacy	
was	associated	with	higher	levels	of	nonadherence.	We	can	interpret	
this	 result	 from	2	perspectives.	First,	patients	picking	up	 their	med-
ication	 from	 a	 pharmacy	 might	 receive	 extra	 adherence-	enhancing	











Paents who filled out 




- Paents who declined to parcipate: n= 244
- Paents who died before compleng the 
quesonnaires: n= 36
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which	allows	especially	close	follow-	up,	might	reflect	the	physician’s	
perception	of	a	higher	nonadherence	risk.
As	 expected,	we	 found	 that	 the	meso-	level	 “clinicians	 reporting	
that	patients	known	to	be	nonadherent	were	targeted	with	adherence	
interventions”	 factor	 was	 associated	 with	 lower	 nonadherence.	





Variable Odds ratio (95%CI) P- value
Block 1: Patient level: Integrative Model of Behavioral Prediction (IMBP) (n = 1377; R² = 12.3%)
Barriers	to	take	immunosuppressants	as	prescribed	 11.90	(7.02-	20.20) <.0001
Intention	to	take	the	immunosuppressants 0.81	(0.66-	0.99) .04
+ Block 2: Patient level: Integrative Model of Behavioral Prediction (IMBP) (n = 1378; R² = 11.6%)
Barriers	to	medication	taking 9.83	(5.76-	16.79) <.0001
Self-efficacy with medication taking 0.90 (0.82-0.99) .04
+ Block 3: Literature derived patient- level variables (n = 1363; R² = 14.7%)
Barriers	to	take	immunosuppressants	as	prescribed 11.60	(6.70-	20.01) <.0001
Currently smoking or stopped <1 y ago 2.00 (1.26-3.18) .003
Employment: Looking for a job vs (Self-)employed 0.85 (0.38-1.91) .69
Employment: Disability vs (Self-)employed 0.67 (0.47-0.96) .03
Employment: Retired vs (Self-)employed 0.49 (0.33-0.72) .0003
Employment: Other vs (Self-)employed 0.53 (0.34-0.86) .01







Frequency of having someone helping to read health-related materials 0.85 (0.77-0.95) .004








Medication pick-up at physician’s office 2.37 (1.23-4.57) .01
Clinicians reporting that non-adherent patients were targeted with adherence interventions 0.64 (0.48-0.87) .004
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Finally,	 at	 the	macro level,	 congruent	with	 previous	 evidence	 in	
chronic	 illness,	 monthly	 out-	of-	pocket	 expenses	 for	 immunosup-
pressants	were	 a	 risk	 factor	 for	 nonadherence.59,60 A recent inter-
national	 survey	 showed	 that	 out-	of-	pocket	 expenses	 are	 especially	
problematic	 in	 the	United	 States,	 but	 also	 in	Canada	 and	Australia.	
Furthermore,	 difficulty	 paying	 medical	 bills	 is	 an	 increasing	 issue	
in	a	number	of	 countries.61	Responding	 to	a	 survey,	70%	of	kidney	
transplant	programs	in	the	United	States	reported	that	patients	had	
difficulties	paying	 for	 their	medication.62	As	health	 insurance	status	
was	not	retained	in	our	analysis,	previous	evidence	from	US	studies	




in transplantation2—a	multilevel	 intervention	approach	 targeting	not	







ence interventions65	 highlight	 the	 value	 of	 complex	 multicompo-
nent	 interventions	 featuring	 support	 by	 both	 family	members	 and	
healthcare	 workers	 (including	 pharmacists).	 However,	 despite	 ad-
dressing	 adherence	 barriers	 via	 tailored	 education,	 counseling,	 or	
daily	 treatment	 support,	 they	 have	 shown	 no	 significant	 improve-







Limitations	 of	 this	 study	 include	 the	 cross-	sectional	 design,	





support,	 thus	 potentially	 jeopardizing	 the	 willingness	 of	 centers,	
clinicians,	 and	 patients	 to	 participate	 in	 the	 study.	While	 assay	 is	
in	standard	use	for	immunosuppressant	monitoring,	a	recent	study	
demonstrated	the	validity	of	the	Medication	Level	Variability	Index	
to	assess	nonadherence	 to	 tacrolimus	 in	 liver	 transplant	groups.68 
We	decided	not	 to	use	assay	 for	 several	 reasons.	First,	 transplant	
centers	 differed	 regarding	 the	 types	 of	 immunosuppressive	 reg-
imens	 prescribed	 (ie,	 63%	 tacrolimus	 based,	 32%	 cyclosporine	
based),	 and	 no	 similar	 validated	 formula	 exists	 for	 adherence	 de-
tection	in	cyclosporine-	based	regimens.	Moreover,	unavailability	of	
electronic	medical	records	in	about	one	fourth	of	the	participating	
centers	 complicated	 retrieval	 of	 assay	 values.	 Pharmacy	 refill	 re-
cords	were	not	uniformly	available	in	all	centers.	We	therefore	used	
a	 validated	 interview	 to	 document	 adherence.	 Another	 limitation	
of	this	study	is	that,	although	we	included	a	large	set	of	multilevel	
factors,	more	work	is	needed	to	identify	relevant	factors,	not	only	
at	 the	patient	 level,	 but	 especially	 at	 the	micro,	meso,	 and	macro	
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